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Abstract
Strategies to prevent HIV infection using pre-exposure prophylaxis (PrEP) are required to curtail
the HIV pandemic. The mucosal tissues of the genital and rectal tracts play a critical role in HIV
acquisition, but antiretroviral (ARV) disposition and correlates of efficacy within these tissues are
not well understood. Pre-clinical and clinical strategies to describe ARV pharmacokinetic-
pharmacodynamic relationships (PK/PD) within mucosal tissues are currently being investigated.
In this review, we summarize the physiochemical and biologic factors influencing ARV tissue
exposure. Further, we discuss the necessary steps to generate relevant PK/PD data and the
challenges associated with this process. Finally, we suggest how pre-clinical and clinical data
might be practically translated into optimal PrEP dosing strategies for clinical trials testing using
mathematical modeling and simulation.
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Antiretroviral therapy (ART) has saved millions of lives and greatly increased the life
expectancy of individuals living with HIV.1 The Joint United Nations Programme on HIV/
AIDS (UNAIDS) set a goal of having 15 million individuals living with HIV on ART by
2015, reaffirming that widespread ART implementation is a global priority.2 It is well
recognized that these drugs penetrate into the genital tract and decrease viral shedding.3-5
Antiretroviral therapy, therefore, was postulated to and could potentially prevent
transmission and acquisition of HIV. Indeed, pharmacologic interventions aimed at
preventing the spread of HIV utilizing currently approved antiretroviral (ARV) medications
have shown success in various settings.6-8
Most recently, the successful use of ART for prevention of transmission has focused on the
use of these agents to prevent HIV acquisition.9-12 If ART stops replication in an HIV-
positive individual and prevents transmission, it is reasonable to think that ART can also
prevent transmission in an HIV-negative individual when confronted with a replication-
competent founder virus. Accordingly, pre-exposure prophylaxis (PrEP) using topical or
systemic (oral or injectable) ARVs to prevent HIV infection around the time of exposure
makes the issue of drug penetration into genital and rectal mucosal tissues critically
important. Many factors can affect drug concentrations and the concentration-response
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relationship in these tissues, and not all are fully understood. This review will summarize
these factors, and propose how they may contribute to achieving protective concentrations
and effective dosing strategies for PrEP. We will also address the limitations of the methods
currently used to generate these data and suggest ways to improve the applicability of the
results.
Evolution of Drug Concentration Data in Mucosal Tissues
Evaluation of drug exposure in female genital and in colorectal tissues began in the 1970s.
Early publications examined the distribution kinetics of antibiotics in these tissues with the
goal of identifying ideal candidates for surgical prophylaxis in gynecologic and colorectal
surgery.13 These pharmacokinetic studies of antibiotic distribution in the surgical setting
continued throughout the 1980s.14,15 Additional investigations identified antibiotics that
were wellsuited for the outpatient treatment of gynecologic infections.16-18 Measures of
drug exposure in these early studies typically consisted of single concurrent tissue and serum
samples obtained after a single dose of antibiotic and were reported as a tissue: plasma ratio.
Later studies conducted more rigorous examinations, utilizing single and multiple dose
kinetic data to report tissue: plasma ratios.19-21 Due to different distribution characteristics
in tissues compared to plasma, single time point concentration ratios could over- or under-
estimate true tissue exposure.19 Therefore, a more comprehensive measure of drug exposure
in these tissues, the area under the concentration-time curve (AUC), was utilized to calculate
tissue:plasma AUC ratios. These early studies made it clear that drug concentrations at sites
of action cannot be assumed to be the same as plasma concentration, and that the ability of
drugs to penetrate into tissue can vary greatly even among members of the same drug class,
which may prove quite important in clinical trial and clinical results.22
Mucosal tissues of the vagina, cervix, and colorectum are a primary target for early HIV
infection and replication.23 Simian immunodeficiency virus (SIV) pathogenesis research in
macaques has demonstrated rapid viral penetration into genital and rectal tissues after local
inoculation. Viral DNA has been detected in the vaginal epithelium within hours after
inoculation, and founder populations of virus can be detected in cervicovaginal tissues as
early as 24 hours post-inoculation.24-26 Clinical studies have confirmed cervical, vaginal,
and colorectal transmissibility of HIV.27-29
While initial viral populations are small, rapid local and systemic dissemination occurs
during the first 4 days of infection, making this time period a critical target for
pharmacologic interventions.24 Therefore, an important determinant in successful PrEP must
be the ability of ARVs to achieve and sustain adequate concentrations in the mucosal tissue,
whether through topical or systemic administration. In order to prevent the index infection in
the new host, sufficient concentrations of ARVs must be present at the time of exposure and
for some yet-to-be-defined length of time afterwards. Penetration of ARVs into the
colorectum, semen, and tissues of the female genital tract (FGT) has been extensively
researched.19,20,30-33 The resulting data have revealed a high degree of variability in
penetration, both between and within drug classes.
The penetration profiles for the ARVs are summarized in Figure 1.19-21,30,31,33-42 Oral ARV
formulations comprise the majority of penetration data. Generally, the nucleoside/tide
reverse transcriptase inhibitors (NRTIs) achieve high concentrations in the female genital
tract. Zidovudine (ZDV), emtricitabine (FTC), and lamivudine (3TC) all have steady-state
and non-steady state tissue:plasma AUC ratios greater than 1.00. Ratios of protease
inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are more
variable, with most PIs having poor penetration (<0.20) into the FGT and NNRTIs having
highly drug-specific penetration. The CCR5 antagonist maraviroc (MVC) penetrates well
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into the FGT (AUC ratio 1.9-2.7), while the integrase strand transfer inhibitor raltegravir
(RAL) shows moderate penetrative ability (AUC ratio 1.00 in HIV negative women and
4.00 in HIV positive women, driven primarily by differential blood plasma exposure).35
There are some inconsistent trends in penetration between single and multiple doses. In the
case of efavirenz (EFV), stavudine (d4T), and atazanavir (ATV), the extent of penetration is
constant regardless of the number of doses given, reflecting a constant relationship between
systemic and local exposure. However, for tenofovir (TFV), abacavir (ABC), and lopinavir
(LPV), drug exposure declines in the genital tract with repeated dosing. The tissue:plasma
AUC ratio declines from 1.1 after a single dose to 0.75 after multiple dosing for TFV, from
0.21 to 0.08 for ABC, and from 0.17 to 0.08 for LPV. This suggests that, with repeated
dosing, entry mechanisms for some ARVs either become saturated, up-regulated (e.g. efflux
transporters) or down-regulated (e.g. uptake transporters), decreasing the ability of these
drugs to reach the FGT.
The pharmacokinetic profiles of alternative ARV formulations have also been studied.
Topical tenofovir (TFV) gel has been successful in preventing HIV infections in clinical
trials, and achieves favorable tissue concentrations when applied vaginally or rectally as
either a gel or a ring.43,44 This formulation has also been shown to rapidly distribute
between vaginal and rectal tissue after application to either site, although the exposure in the
non-dosed site reaches only approximately 5% of the exposure seen at the site of dosing.43
A study in 24 HIV-negative women showed that a vaginal ring formulation of dapivirine
achieved cervicovaginal fluid (CVF) concentrations that were 3 log units higher than plasma
concentrations and 4 log units higher than the reported in vitro EC50 of HIV-1 (LAI).45
Further, a novel NNRTI rilpivirine (RPV) has shown penetration AUC ratios of 1.2-1.95 in
CVF and 0.48-1.0 in vaginal tissue when administered as a long acting injectable
formulation.41
Factors Influencing Drug Entry into Tissues
The data described above highlight the need to identify the variables affecting mucosal
penetration of small molecules. Once these variables are understood, they can be considered
in the ARV development process and help identify ideal drug candidates for PrEP.
There are several physiochemical factors that influence tissue penetration: blood perfusion,
protein binding, molecular size, lipophilicity, ionization state, and membrane transporter
affinity. Adequate tissue blood flow is a necessary requirement for drug efficacy,
particularly for drugs that are efficiently metabolized by target organs, also called “high
extraction compounds”. For highly-extracted drugs, there is a direct relationship between
tissue perfusion and drug entry into tissues, and lack of perfusion is a likely contributor to
the difficulty of treating infections at certain anatomic sites (e.g. CNS, bone, etc). One of the
primary determinants of pharmacodynamic efficacy is the fraction of unbound drug
available to cross cellular membranes and enter tissues and cells.46,47 Differential protein
binding between two similar drugs can have large pharmacodynamic implications. For
example, it has been shown that ARVs which are highly protein-bound (e.g. EFV, LPV)
have much lower exposure in tissues than those which have less protein binding (e.g. FTC,
TFV).19 Chemical characteristics can also affect drug entry into tissues and cells, mostly by
affecting the ability of a compound to diffuse across cellular membranes. Perhaps the most
well-established characteristic is the inverse relationship between the molecular size of a
drug and its penetrative capability.46 An additional factor is the lipophilicity of a drug.
Highly lipophilic compounds (e.g. propranolol) are able to cross cellular membranes much
more easily (and have better intestinal absorption) compared to hydrophilic drugs (e.g.
hydrochlorothiazide). This is an important consideration in drug development, where
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formulation changes can occur as a result of poor intestinal absorption. Finally, the
ionization state of a compound, which is determined by its pKa, is another element that can
aid or hinder diffusion across membranes. Drugs that are mostly ionized at physiologic pH
(e.g. ZDV) are much less likely to enter tissues and cells compared to drugs that are neutral
at an identical pH (e.g. FTC). It should be noted that while a drug’s pKa is unchanging; its
ionization state can differ among tissues due to local pH changes. For example, an acidic
environment (e.g. prostatic fluid; pH 6.6) can cause a drug with a pKa >6.6 (e.g. ZDV; pKa
9.68) to be ionized and trapped.48,49
In addition to physiochemical properties, the effect of transporter expression and differences
in transporter affinity among ARVs may play a critical role in determining mucosal
penetration. The effect of transporters on ARV uptake and elimination from tissues has been
thoroughly evaluated. A review by Kis and colleagues summarizes the inhibitory and
induction effects of ARVs on the ATP-binding cassette (ABC) and solute carrier (SLC)
transporter families, which are known to contribute to ARV penetration into various tissues
and compartments.50 Briefly, the efflux transporters of the SLC family, especially p-
glycoprotein (P-gp), are the primary method of cellular efflux for almost all ARVs with the
exception of the NNRTIs. Transporters responsible for ARV uptake are more varied, but are
generally comprised of the organic anion transporters (OATPs). Importantly, all ARVs with
the exception of RAL inhibit and/or induce one or more of these transporters to some
degree, irrespective of whether they are substrates for the transporters. This has implications
not just for drug disposition in tissues, but also for drug-drug interactions. Notably, the
authors mention a lack of data on the expression of these transporter groups in the FGT
despite adequate expression data in other compartments. One study examined P-
glycoprotein (P-gp) localization by immunohistochemistry staining in the upper genital tract
of 14 women and found P-gp expression in the ovaries, fallopian tubes, corpus luteum,
ectocervix and endocervix, though the degree of expression was highly variable between
patients and tissues.51 Additional publications on transporter expression in the FGT are
severely lacking. A recent study examined the expression of uptake (OAT1, OAT3,
OATP1B1) and efflux (MDR1, MRP2, and MRP4) transporters in vaginal, cervical, and
rectal tissue.52 Gene expression of the efflux transporters was variable between subjects but
consistently expressed, whereas uptake transporters were rarely expressed in these tissues.
Similar trends were observed in protein levels, and are supported by drug disposition data.
The inability to visualize the distribution of ARVs within mucosal tissues hinders the
progress of PrEP research. Even for ARVs that are known to permeate well into FGT and
colorectal tissue, there are few data evaluating drug exposure in specific areas or cellular
subsets vulnerable to HIV infection (i.e. mucosa vs. submucosa vs. lymphoid aggregates;
mononuclear versus epithelial cells). Techniques that would allow visualization and
quantification of ARVs in tissues would be invaluable not only for prevention, but also for
treatment and eradication strategies. One such approach is matrix-assisted laser desorption/
ionization (MALDI): a mass spectrometry technique that has been used since the 1980s for
peptide identification.53 Through the use of multiple laser ionizations, MALDI is able to
generate information about relative concentrations of tissue constituents which, when
coupled with imaging software, allow for the visualization of target analytes within a tissue.
Recently, this technique has been modified to identify small molecules within specific tissue
areas and even within individual cells.54,55 MALDI has been used previously to quantify
ARVs in plasma and represents a promising approach to understanding drug disposition in
tissues.56
Another possible avenue for future research could include the use of a quantitative structure
activity relationship (QSAR) model to isolate the chemical moieties and pharmacokinetic
parameters (e.g. protein binding) that improve or hinder penetration. These models have
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been successfully used to identify structural characteristics that enhance HIV inhibition, but
to date, no validated QSAR model has been developed for ARV penetration into the
mucosal compartment.57 This model was used to determine penetration of drugs across the
blood-brain barrier (BBB) and achieved a positive predictive value of 100% and negative
predictive value of 83%.58 The authors were also able to identify factors, such as binding
affinity to efflux transporters, which affect BBB penetration. We recently used a similar
approach to develop a QSAR model for drug entry into female genital tissues, utilizing a
newly validated QSAR model for transporter affinity.59 Our model was modestly predictive,
and identified MRP4 as a novel contributor to FGT penetration.60 Validation of this model
and/or the addition of other models of drug penetration into vaginal/cervical and rectal
tissues would greatly inform the drug development process and identify PrEP candidates
from an early stage.
Finally, biological factors can affect both ARV penetration into tissues and infection
susceptibility. For example, the N(t)RTIs require intra-cellular phosphorylation to their
active forms through cellular kinase activity. It has been determined that kinase activity in
quiescent or activated cells changes the rate and extent of phosphorylation of ARVs.
Specifically, zalcitabine, lamivudine, stavudine, and didanosine are preferentially
phosphorylated in activated cells.61,62 No noted differences in phosphorylation have been
found between activated and quiescent cells for tenofovir.63 Importantly, these differences
in active metabolite concentrations may not correlate with anti-viral activity, as zalcitabine,
lamivudine, and didanosine are more active against HIV in quiescent cells despite lower
metabolite concentrations than in active cells.62 It may be that increased numbers of
endogenous nucleotides in activated cells decrease their effectiveness.
Altered mucosal integrity may also result in large inter-individual variability in ARV
penetration, particularly for topical dosage forms. Compromised mucosal integrity has been
associated with increased viral penetration.64 It is not known whether this relationship holds
true for topical ARV penetration, but inflammation and physical breaks in skin are known to
increase plasma exposure to topical products. Further, while the integrity of the upper
genital tract tissues (e.g. endometrium) is heavily influenced by the menstrual cycle,
hormonal influence on the vaginal and rectal mucosa is less understood. There are numerous
studies examining the role of estrogen on HIV susceptibility, however studies exploring the
hormonal influence on drug exposure are lacking.65,66
Drug Persistence and Functional Half-Life
Given that the index infection likely takes place within the mucosa or submucosa of mucosal
tissues, the presence of adequate concentrations of ARVs at the time of exposure is critical
in PrEP. Also critical is the length of time compounds reside in the tissue. Compounds with
long tissue half-lives (or delivery systems with continuous drug exposure) would be favored
for both virologic and adherence factors.9,4,11 For any ARV used in PrEP, the time spent
above target concentration must at least be as long as the length of time that viable virus
remains in the mucosal cavity after coital exposure. The life span of the HIV virion in
plasma has been reported as 6 hours, while HIV-infected CD4+ T cells have a lifespan of
approximately 2 days in plasma.67 The life span of both infected cells and virion in the
mucosal cavity remains unknown and demands exploration. One study examined virion
persistence after vaginal inoculation of SIV in macaques and found that low levels
(hundreds to 104 copies/μg tissue) were present 1 day after inoculation.25 If we assume the
life span in the mucosal cavities are identical to those in plasma, then protective ARV
concentrations would need to be continually present for up to 3 days after each exposure.
Recently, the iPrEX, FemPreP, and VOICE studies have demonstrated that study volunteers
have difficulty adhering to a once-daily dosing regimen, which compromises PrEP
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efficacy.9,11,12 These studies demonstrated that daily prophylaxis against HIV infection
(whether oral or topical) will be minimally effective if the functional half-life is too short, or
the mucosal tissue penetration too low, to permit any reasonable degree of tissue protection.
TFV and FTC have reported plasma half-lives of 17 and 10 hours, respectively. However
the half-lives of their active intracellular metabolites (TFV-dp and FTC-tp) in PBMCs are
much longer at approximately 144 and 38 hours, respectively.68,69 In mucosal tissues, we
have documented that TFV-dp and FTC-tp have half-lives of 2-6 days.30 We have also
noted that the high TFV and TFV-dp exposures achieved in colorectal tissue (100X higher
than vaginal or cervical tissue) after a single dose were advantageous to the iPrEX cohort of
men who have sex with men who did not take daily tenofovir/emtricitabine (Truvada) as
instructed but rather intermittently and yet were still protected from HIV infection.9,70
Despite potential advantages in PrEP, a number of concerns are inherent with a long half-life
compound: in particular, the development of resistance. Due to an increase in elimination
time, there may be extended periods where drug concentrations are sub-therapeutic in
mucosal tissues. If HIV transmission occurs during this time, prolonged exposure to sub-
therapeutic drug concentrations has the potential to select for viral resistance.71 This is
especially true for long-acting injectables, where subtherapeutic concentrations may persist
for weeks, rather than hours.41 Obviously, allergic reactions might also be exacerbated with
unremitting exposure to an allergen as was observed with penicillin and serum sickness.72
Generating Effective Drug Target Concentrations and Dosing Strategies
In order to ensure adequate ARV drug concentrations within mucosal tissue, therapeutic
tissue concentration targets must be defined. To date, target ARV tissue concentrations for
HIV prevention have not been established, but if determined would represent an important
advance in PrEP research. Once the appropriate models for defining these are identified,
dosing strategies can be designed to achieve concentrations above this target while
preventing long periods of subtherapeutic drug exposure and minimizing the risk of drug
resistance.
The variable efficacy of topical and systemic PrEP observed in clinical trials is highly
dependent on adherence, but is also due to limited mucosal tissue penetration for the ARVs
studied thus far. Numerous methods are currently under investigation to identify those drugs
and concentrations that successfully prevent HIV infection upon exposure to the virus.
These include cellular studies, humanized mice and nonhuman primate models, the human
mucosal tissue explant model, and retrospective analysis of clinical trial data.73-75 The
generation of “threshold” ARV concentrations above which HIV transmission is unlikely
would provide a target around which dosing strategies could be generated for clinical
studies.
Pharmacodynamic measures of efficacy, such as time above MIC, have been successfully
implemented as targets to guide antibiotic dosing. Similar measures of efficacy need to be
developed for HIV chemoprophylaxis. The process is complex, requiring dose fractionation
to determine the best efficacy target.76 Unfortunately, establishing target concentrations in
mucosal tissues is a complex process. For example, while bacterial infections are
extracellular, and the concentration of antimicrobials in the interstitial fluid is
pharmacodynamically active (and can be measured with dialysis techniques or in blister
fluid), the intracellular nature of HIV requires an understanding of active intracellular
concentrations.76,77 Based on the physicochemical and biological factors listed above, it is
therefore more important to understand protein-unbound drug concentrations in tissues or
cells, rather than plasma. Further, due to differences in rates of tissue distribution, single
time-point estimates of drug concentration may be inadequate to fully describe these
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pharmacokinetic-pharmacodynamic relationships, and multiple sampling to quantify area
under the concentration time curve (AUC) is necessary. With newer technologies such as
MALDI imaging, simultaneously exploring the pharmacokinetics and pharmacodynamics of
drug distribution and effect tissues may be possible.
Pharmacokinetic modeling and simulation approaches can identify optimal (preferably
coitally-independent) dosing strategies for clinical trial investigation which surpass the
target mucosal tissue concentrations for a predefined critical length of time. 78-80 Indeed, it
would be unreasonable to identify a target concentration that was only achievable by dosing
multiple times per day, as even once daily dosing has been challenging for some clinical
study subjects to adhere to. Adherence has been shown to correlate with efficacy in multiple
studies and has been thoroughly reviewed by Koenig and colleagues.10,81,82 The factors
affecting drug adherence are complex, but the frequency and complexity of the dosing
regimen in a healthy population is certainly a contributing factor.83 Several novel
formulations are currently in development and may be useful to overcome the adherence
barrier.84 For example, a long-acting parenteral ARV formulation or a slow-release vaginal
ring formulation should increase the probability of achieving consistent target
concentrations. It has yet to be determined if these drug delivery modalities will be
acceptable to study volunteers and utilized more consistently than daily dosed products.
Future Directions in Prevention Pharmacology
The necessity of an effective prophylactic regimen is highlighted by the inability of
treatment regimens to completely prevent viral shedding in genital and rectal tissues. HIV
RNA is easily detectable in the genital tissues and fluids of HIV-infected women and in the
seminal fluid and rectal tissue of HIV-infected men and is highly correlated with plasma
RNA levels.85-87 Importantly, viral shedding is reduced by ART by as much as 2 log units;
demonstrating that therapy likely reduces the infectivity of HIV-infected individuals.5,88
Reduced viral shedding can have profound clinical implications. The HPTN 052 study
demonstrated that among serodiscordant couples, early initiation of ART in the infected
partner was associated with a 96% reduction in HIV transmission compared to deferred
initiation.6 The large decrease in transmission observed in this study would not have been
possible without decreased viral shedding. Unfortunately, both genital and rectal shedding
have been shown to persist even in the setting of undetectable plasma viral RNA.89-91 While
it is unknown whether the viral RNA found in these tissues represents viable and infectious
HIV, it is a concerning finding nonetheless. The apparent inability of treatment regimens to
eradicate HIV in the genital tract suggests that effective PrEP will require novel dosing
strategies or dosage forms to prevent infection at these sites. What remains unclear is
whether a disparity exists between effective ARV concentrations for prevention of
acquisition via PrEP versus prevention of transmission via treatment. Concentration-
response relationships are well characterized for ARVs in plasma, but have not been studied
at the tissue level. It is possible that differences in immune cell populations between plasma
and tissue have an effect on drug efficacy. For instance, higher levels of HIV targets in
rectal tissue compared to plasma may require higher concentrations of drug at this site to
prevent infection.28
The in vitro and pre-clinical methods developed to understand ARV pharmacokinetics and
efficacy in mucosal tissue compartments have greatly improved our understanding of ARV
pharmacology. However, these are not without limitations. Nonhuman primate models of
prevention are limited by the numbers available for study, and have some clinically relevant
pharmacologic and virologic distinctions. The humanized mouse model can use clinically
relevant viruses but challenges remain in characterizing pharmacologic differences with
smaller sampling capacity.73 The human tissue explant model can use relevant tissue and
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viruses, but data on ARV disposition and PK-PD relationships are lacking, as are
standardized methods and approaches.74 Target effective ARV concentrations can be
generated from all these models, but a lack of robust and consistent data across all models
currently limit our ability to determine how they should be utilized for informing drug
development go/no go decisions and clinical trial design. As previously indicated, PK
modeling is critical for generating dose-concentration relationships even in early drug
development and should be used for PrEP.92-94 Simulations run on a successful PK model
will identify which dosing regimen best achieves target concentrations, once identified. This
information will streamline trial development and increase the likelihood of success. The use
of modeling and simulation for dosing regimen selection and clinical trial design is an
important cost-effective technique, particularly in chemoprophylaxis studies whereby
clinical dose-finding studies are unattainable due to patient risk and sample size
requirements. Models can be generated which take into account what is already known
about a drug and factor in various assumptions, such as intra- and inter-patient variability,
adherence, and dropout rates.95,96 These strategies have been used in the past for faster
market approval.97 An additional benefit of modeling is that once generated, a model can be
used not only to evaluate the drug for which it was developed, but for other drugs within that
class as well.95 This will be extremely beneficial for PrEP, with multiple candidates being
available in similar therapeutic drug classes.
Conclusion
Successful HIV prevention strategies have been demonstrated in clinical trials, but
implementation in the real world is a challenge. Use of ARV treatment as prevention has
already become policy in the setting of discordant couples, and may be expected to inform
when ART is started and continued and which drugs are selected.98,99 Curing HIV infection
will require that ART stop replication in every compartment, a feat which has already
proven a challenge. The mixed results of both topical and systemic PrEP trials demand
preclinical and early phase strategies to improve the knowledge of efficacy targets and
develop maximally effective dosing strategies that will be accepted by study participants and
eventually the target market. The mucosal compartment plays an important role in
transmission as the site of first exposure to HIV. Therefore, research aimed at understanding
drug targets to prevent infection at this location, or even distal to this location (e.g. regional
lymph nodes) is essential for developing successful next generation PrEP strategies.
Determining the optimal time that drug should reside in mucosal tissues will also help define
dosing strategies. Factors influencing tissue disposition are poorly understood, but should be
identified so that chemicals and formulations can be optimally designed for this purpose.
Validating animal and ex vivo models against clinical outcomes in humans will determine
their utility in making go/no go decisions and informing clinical trial design. Finally,
pharmacokinetic/pharmacodynamic and clinical trial modeling and simulation have an
important role to play in potentially informing the drug development process and increasing
the probability of PrEP success in large clinical trials.
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Figure 1. A&B: ARV Penetration into Mucosal Tissues
Data are from references 19-21, 30, 31, 33-42. 3TC=lamivudine, FTC=emtricitabine,
TFV=tenofovir, ZDV=zidovudine, ddI=didanosine, d4T=stavudine, ABC=abacavir,
DRV=darunavir, IDV=indinavir, ATV=atazanavir, APV=amprenavir, SQV=saquinavir,
LPV=lopinavir, RTV=ritonavir, NVP=nevirapine, EFV=efavirenz, ETV=etravirine,
RPV=rilpivirine, RAL=raltegravir, DTG=dolutegravir, MVC=maraviroc, NRTI=nucleoside
reverse transcriptase inhibitor, PI=protease inhibitor, NNRTI=non-nucleoside reverse
transcriptase inhibitor, INSTI=integrase strand transfer inhibitor, RA=receptor anatagonist
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